Eversense 365 CGM Study Reveals Strong Diabetes Management Results Over One Year

A large real-world study has shown strong results for the Eversense 365 continuous glucose monitoring (CGM) system. Over 12,000 sensors were analysed, with users meeting key diabetes management targets. The data highlights high adherence and improved glycemic control among patients using the long-term implantable device.

The study also examined performance when paired with the twiist automated insulin delivery (AID) system, revealing even better outcomes for a smaller group of users. Senseonics Holdings, Inc., the maker of Eversense 365, produces the only one-year CGM system currently available. Designed for long-term wear, it provides continuous glucose readings with minimal interruptions. The company’s latest study tracked 12,360 sensors in open-loop users, measuring adherence, glucose metrics, and hypoglycemic results.

On average, participants achieved a mean Time In Range (TIR) of 66.16% and a Glucose Management Indicator (GMI) of 7.16%. Over 81% of users met their hypoglycemic targets. Performance remained consistent across both the first and second six-month wear periods.

An additional 153 sensors were monitored in combination with the twiist AID system for at least 30 days. This group showed even stronger results, with a mean TIR of 76.08% and a GMI of 6.78%. Users also maintained a median sensor wear time of 99.46%, indicating high reliability and patient engagement.

The findings suggest that combining Eversense 365 with twiist helps people reach glycemic goals more effectively. The system’s long-term accuracy and minimal disruptions contribute to better diabetes management overall. The study confirms that Eversense 365 delivers steady glucose monitoring over its full one-year lifespan. Users consistently met key metrics, with even greater improvements when paired with the twiist AID system. These results reinforce the device’s role in supporting long-term diabetes care.